Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics
Tirzepatide was noninferior to dulaglutide in reducing a composite of cardiovascular events in people with type 2 diabetes and existing heart disease.Both agents are currently approved for type 2 diabetes,…